Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
Bryan Unger, Director of Business Development at Microvascular Therapeutics, reposted from NuvOx Therapeutics on LinkedIn:
”Proud to share that the first patient has been enrolled in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion.
Stroke is one of the leading drivers of long-term disability and healthcare costs, with lifelong care representing a substantial burden for patients, families, and health systems.
Our Phase IIa data for NanO₂ showed strong potential in reducing this burden.
Reaching the first patient enrolled is a critical milestone.
We are grateful to the clinical teams and partners who are advancing this work.”
Quoting NuvOx Therapeutics‘s post:
”We have enrolled the first patient in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion (LVO).
NOVEL is a multicenter, randomized, placebo-controlled study funded by the NIHR (National Institute for Health and Care Research)–MRC EME Programme, and co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.
This milestone advances NanO₂, designed to rapidly improve tissue oxygenation, toward addressing one of the most severe and costly forms of stroke.
We thank our clinical collaborators and funding partners as we activate additional sites and accelerate enrollment.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers